Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Ainos Inc (AIMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/06/2025: AIMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -72.86% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/06/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.42M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 305468 | Beta 2.22 | 52 Weeks Range 0.40 - 1.07 | Updated Date 06/19/2025 |
52 Weeks Range 0.40 - 1.07 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2978.02% |
Management Effectiveness
Return on Assets (TTM) -30.93% | Return on Equity (TTM) -82.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20792929 | Price to Sales(TTM) 107.54 |
Enterprise Value 20792929 | Price to Sales(TTM) 107.54 | ||
Enterprise Value to Revenue 195.78 | Enterprise Value to EBITDA -1.6 | Shares Outstanding 20960200 | Shares Floating 6849910 |
Shares Outstanding 20960200 | Shares Floating 6849910 | ||
Percent Insiders 61.55 | Percent Institutions 0.55 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ainos Inc
Company Overview
History and Background
Ainos, Inc., formerly known as Mouse Chain, Inc., was founded in 2004 and is headquartered in San Diego, California. The company focuses on developing innovative medical technologies.
Core Business Areas
- Virend Technology Platform: Ainos's core technology platform, Virend, is focused on developing antiviral and immunomodulatory therapeutics. It is designed to combat viral infections and modulate the immune system. The product candidate using this technology is VELDONA.
- Low-Dose Interferon Technology: The company leverages low-dose interferon (IFN) technology to develop therapeutic products for various indications. This approach aims to harness the antiviral and immunomodulatory properties of IFN at lower dosages to minimize side effects.
- Herbal Medicine: The company is engaged in creating consumer healthcare products based on herbal medicine that prevent the common cold, influenza, and COVID-19.
Leadership and Structure
Ainos Inc's leadership team includes the CEO and other key executives responsible for strategic direction and operational execution. The organizational structure comprises departments dedicated to research and development, clinical trials, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- VELDONA: VELDONA is an investigational low-dose oral interferon alpha formulation for treating recurrent respiratory infections, including upper respiratory tract infections. Market share data is not currently publicly available as the product is still in clinical trials. Competitors would include pharmaceutical companies that produce antiviral medications, such as Pfizer (PAXLOVID) and Gilead Sciences (Tamiflu).
- Ainos Flora: Herbal medicine supplement that uses essential oils known to have antiviral effects. Market share data is not currently publicly available. The company is engaged in creating consumer healthcare products based on herbal medicine that prevent the common cold, influenza, and COVID-19. Competitors include Reckitt Benckiser (Lemsip, Strepsils), Procter & Gamble (Vicks), and Johnson & Johnson (Tylenol).
Market Dynamics
Industry Overview
The pharmaceutical and biotechnology industry is characterized by intense competition, rapid technological advancements, stringent regulatory requirements, and high research and development costs. The market for antiviral therapies and immunomodulatory agents is significant and growing, driven by the emergence of new infectious diseases and the increasing prevalence of chronic conditions.
Positioning
Ainos Inc positions itself as an innovative player in the antiviral and immunomodulatory therapeutics market, focusing on leveraging its Virend platform and low-dose interferon technology to address unmet medical needs. Their competitive advantage lies in their novel approach and potential to develop differentiated products.
Total Addressable Market (TAM)
The antiviral therapeutics market is expected to reach billions of dollars. Ainos is positioned to capture a portion of this TAM with VELDONA, targeting recurrent respiratory infections. No specific TAM number provided by Ainos.
Upturn SWOT Analysis
Strengths
- Innovative Virend technology platform
- Focus on low-dose interferon therapeutics
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Lack of commercialized products
- High regulatory hurdles
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Government funding for research and development
- Increasing demand for antiviral and immunomodulatory therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory setbacks
- Clinical trial failures
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- PFE
- GILD
- MRK
Competitive Landscape
Ainos is a small, development-stage company competing with much larger, established pharmaceutical companies. Ainos's advantage lies in its innovative technology, while its disadvantage is its limited resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not available.
Future Projections: Future projections are not available.
Recent Initiatives: Ainos recent initiatives include advancing VELDONA through clinical trials and the development of herbal medicine supplements.
Summary
Ainos Inc. is a development-stage company focused on innovative antiviral and immunomodulatory therapeutics. It has a promising technology platform but faces significant challenges related to funding, regulatory approvals, and competition. Success depends on clinical trial outcomes and strategic partnerships. The company's financial health is not available, which increases the risk level.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ainos Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2013-11-04 | CEO, President & Chairman of the Board Mr. Chun-Hsien Tsai | ||
Sector Healthcare | Industry Medical Devices | Full time employees 44 | Website https://www.ainos.com |
Full time employees 44 | Website https://www.ainos.com | ||
Ainos, Inc., a healthcare company, focuses on the development of novel point-of-care testing therapeutics based on very low-dose interferon alpha and synthetic RNA-driven preventative medicine. The company provides COVID-19 antigen rapid test kit and VELDONA pet supplement, a health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. It offers VELDONA human and animal drugs, a human drug pipeline includes treatments for oral warts in HIV-seropositive patients, Sjögren's syndrome, common cold, and influenza; VOC POCT " Ainos Flora designed to offer a quick, non-invasive test for female vaginal health and common STIs; and VOC platform " NISD co-development sensing platform based on AI Nose. In addition, the company provides VOC POCT " Ainos Pen, a cloud-connected, multi-purpose, portable breath analyzer that is intended to monitor health conditions within minutes; VOC POCT " CHS430 provide non-invasive testing for ventilator-associated pneumonia within few minutes, as compared to current standard of care invasive culture tests that typically take more than two days to provide results; and Synthetic RNA develops a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.